Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1).

ABSTRACT:

Background

Brodalumab is efficacious for the treatment of moderate-to-severe plaque psoriasis through 52 weeks.

Objectives

To evaluate the efficacy and safety of brodalumab through 120 weeks, including following withdrawal and retreatment.

Methods

At baseline, patients were randomized to brodalumab (n = 222) or placebo (n = 220). At week 12, patients achieving a static Physician's Global Assessment (sPGA) score of 0 or 1 (sPGA 0/1) with brodalumab were rerandomized to brodalumab (n = 83) or placebo (n = 84; later re-treated with brodalumab if sPGA ≥ 3 occurred), and patients receiving placebo switched to brodalumab (n = 208). Safety was assessed by exposure-adjusted rates of treatment-emergent adverse events.

Results

Among those who achieved sPGA 0/1 at week 12

SUBMITTER: Papp K 

PROVIDER: S-EPMC7754427 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature